Barclays analyst Andrew Mok raised the firm’s price target on Elevance Health to $621 from $584 and keeps an Overweight rating on the shares post the Q1 report. The analyst remains positive on Elevance following its “positively differentiated” cost trend, solid execution in Carelon, and “guarded optimism” in Medicare.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ELV:
- Options Volatility and Implied Earnings Moves Today, April 18, 2024
- Notable companies reporting before tomorrow’s open
- Elevance Health, Inc. (ELV) Q1 Earnings Cheat Sheet
- Centene rises, Molina slides following Floridaâs managed Medicaid awards
- Elevance Health,CD&R in primary care delivery pact, terms undisclosed
